What does the evidence show about Anastrozole's effects?

Read Off Label rates the evidence for Anastrozole as Strong and the benefit magnitude as med, producing an overall grade of B (6.4/10). Routine aromatase-inhibitor use with standard TRT has not shown net benefit; chronic high-dose exposure can produce iatrogenic low-estradiol symptoms.

What safety findings are reported for Anastrozole?

Anastrozole has a med risk profile in the database. Med (excessive estrogen suppression can harm bones, lipids, libido, mood — 'crashing E2' is a common iatrogenic mistake; joint pain; hot flashes) Legal status: Rx.

What doses or routes are reported for Anastrozole?

0.25-0.5 mg 2x/week for TRT users (cautious dosing); breast cancer 1 mg/day This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.

Rankings / Hormones & Endocrine

Anastrozole

Hormones & Endocrine · Aromatase inhibitor

Tier B

Reviewed by Read Off Label · Last reviewed Jun 8, 2026 · How we grade

aromatase-inhibitorandrogen-therapyprescription

6.4 / 10

Tier B

Ev 8 Bn 5 Sf 5

Bottom line

Read Off Label grades Anastrozole as B (6.4/10) based on strong evidence, med benefit magnitude, and a med-risk safety profile.

Routine aromatase-inhibitor use with standard TRT has not shown net benefit; chronic high-dose exposure can produce iatrogenic low-estradiol symptoms.

Studied, labeled, or reported-use context: 0. — Rx; not individualized guidance.

What the evidence says

Routine aromatase-inhibitor use with standard TRT has not shown net benefit; chronic high-dose exposure can produce iatrogenic low-estradiol symptoms. Clinical use generally follows symptomatic and laboratory-confirmed estradiol elevation.

Mechanism

Selective non-steroidal aromatase inhibitor; blocks conversion of androgens to estradiol; approved for ER+ breast cancer; off-label for estrogen management during TRT or AAS cycles

Studied, labeled, or reported dose & route

0.25-0.5 mg 2x/week for TRT users (cautious dosing); breast cancer 1 mg/day

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Anastrozole's effects?: Read Off Label rates the evidence for Anastrozole as Strong and the benefit magnitude as med, producing an overall grade of B (6.4/10). Routine aromatase-inhibitor use with standard TRT has not shown net benefit; chronic high-dose exposure can produce iatrogenic low-estradiol symptoms.
What safety findings are reported for Anastrozole?: Anastrozole has a med risk profile in the database. Med (excessive estrogen suppression can harm bones, lipids, libido, mood — 'crashing E2' is a common iatrogenic mistake; joint pain; hot flashes) Legal status: Rx.
What doses or routes are reported for Anastrozole?: 0.25-0.5 mg 2x/week for TRT users (cautious dosing); breast cancer 1 mg/day This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Anastrozole work?: Selective non-steroidal aromatase inhibitor; blocks conversion of androgens to estradiol; approved for ER+ breast cancer; off-label for estrogen management during TRT or AAS cycles

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.